Vivimed Labs Limited Enters Corporate Insolvency Resolution Process
Vivimed Labs Limited has entered Corporate Insolvency Resolution Process on April 15, 2026, as ordered by NCLT Bengaluru. Creditors must submit claims by May 1, 2026, to the IRP T Narayana Swamy. The estimated closure date for the process is October 11, 2026.
CIRP directly impacts the company's operations, management, and financial standing, leading to a high level of uncertainty and potential for significant restructuring or liquidation.
The initiation of Corporate Insolvency Resolution Process (CIRP) is a significant negative event for a company, indicating severe financial distress.
Vivimed Labs Limited has officially entered the Corporate Insolvency Resolution Process (CIRP). The National Company Law Tribunal (NCLT), Bengaluru Bench, ordered the commencement of this process on April 15, 2026. A copy of this order was received by the company on April 17, 2026.
The company's registered office is located at Plot No. 78-A, Kolhar Industrial Area, Bidar, Karnataka -585403, while its corporate address is GMR Towers, 3rd & 4th Floor, Green Lands, Begumpet, Beside the Plaza Hotel, Hyderabad, Telangana -500016.
Creditors of Vivimed Labs Limited are hereby notified to submit their claims with supporting proof to the Interim Resolution Professional (IRP), T Narayana Swamy (IBBI Regn. No.: IBBI/IPA-002/IP-N0 1078/2020-2021/13427), on or before May 01, 2026. The submission address for the IRP is "VK Commerce", # 8, 3rd Floor, 3rd Main Road, Opp. Rajajinagar IT Park, KSSIDC, Rajajinagar Industrial Estate, Bengaluru, Karnataka -560010. Financial creditors must submit their claims electronically, while all other creditors can submit in person, by post, or electronically. Submission of false or misleading proofs of claim will attract penalties.
The insolvency commencement date is April 15, 2026, and the estimated date for the closure of the insolvency resolution process is October 11, 2026.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under corporate insolvency resolution process. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.